Aligos Therapeutics annual debt-to-equity ratio
2020
2021
2022
2023
2025
Aligos Therapeutics Debt-to-Equity Ratio Growth & History (ALGS)
Aligos Therapeutics's debt-to-equity ratio was 0.10 for fiscal 2025.
View full Aligos Therapeutics company overviewAligos Therapeutics annual debt-to-equity ratio history
| Fiscal year | Period ended | Debt-to-equity ratio | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | 0.10 | — | — |
| 2023 | 2023-12-31 | 0.12 | −0.00 | −0.05% |
| 2022 | 2022-12-31 | 0.12 | 0.04 | +54.66% |
| 2021 | 2021-12-31 | 0.08 | 0.02 | +32.37% |
| 2020 | 2020-12-31 | 0.06 | — | — |
Aligos Therapeutics quarterly debt-to-equity ratio
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Debt-to-equity ratio | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | 0.11 | 0.04 | +62.76% |
| Q1 2026 | 2026-03-31 | 0.14 | 0.07 | +102.51% |
| Q4 2025 | 2025-12-31 | 0.10 | — | — |
| Q3 2025 | 2025-09-30 | 0.08 | −0.10 | −53.69% |
| Q2 2025 | 2025-06-30 | 0.07 | −0.08 | −53.85% |
| Q1 2025 | 2025-03-31 | 0.07 | −0.11 | −61.44% |
| Q3 2024 | 2024-09-30 | 0.18 | −0.03 | −15.10% |
| Q2 2024 | 2024-06-30 | 0.15 | −0.03 | −17.92% |
| Q1 2024 | 2024-03-31 | 0.18 | 0.03 | +24.20% |
| Q4 2023 | 2023-12-31 | 0.12 | −0.00 | −0.05% |
| Q3 2023 | 2023-09-30 | 0.21 | 0.11 | +101.03% |
| Q2 2023 | 2023-06-30 | 0.18 | 0.08 | +81.74% |
| Q1 2023 | 2023-03-31 | 0.14 | 0.05 | +50.13% |
| Q4 2022 | 2022-12-31 | 0.12 | 0.04 | +54.66% |
| Q3 2022 | 2022-09-30 | 0.11 | 0.05 | +86.62% |
| Q2 2022 | 2022-06-30 | 0.10 | 0.02 | +32.24% |
| Q1 2022 | 2022-03-31 | 0.09 | 0.03 | +42.64% |
| Q4 2021 | 2021-12-31 | 0.08 | 0.02 | +32.37% |
| Q3 2021 | 2021-09-30 | 0.06 | — | — |
| Q2 2021 | 2021-06-30 | 0.07 | — | — |
| Q1 2021 | 2021-03-31 | 0.07 | — | — |
| Q4 2020 | 2020-12-31 | 0.06 | — | — |
Aligos Therapeutics debt-to-equity ratio trends
Over the last five fiscal years, Aligos Therapeutics's debt-to-equity ratio increased from 0.06 to 0.10, a change of 0.04. The latest reported quarter, Q2 2026, shows 0.11.
About the metric
What the debt-to-equity ratio means
The debt-to-equity ratio compares interest-bearing debt with shareholders’ equity. It helps show how much debt financing a company uses relative to its accounting equity, but useful comparison levels vary by industry.
Calculation and source
How debt-to-equity is calculated
TickerStat calculates debt-to-equity as total interest-bearing debt divided by SEC-reported shareholders’ equity for the same balance-sheet date. Total liabilities are not treated as debt, and periods with non-positive equity are omitted. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Aligos Therapeutics source filings ↗